Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma

Bone Marrow Transplantation volume 40, pages 759–764 (2007)Cite this article

Abstract

Long-term survivors after autologous peripheral blood stem cell transplantation (APBSCT) for lymphoma or Hodgkin's disease are known to have a high risk of developing myelodysplastic syndrome (MDS), but the risk of MDS is not clear for patients transplanted for myeloma. We reviewed the outcomes for 82 myeloma patients who underwent APBSCT at our center. The group included 47 men and 35 women of median age 56 years (range: 37–74 years). Median time from diagnosis to APBSCT was 8.2 months (range: 2.6–86.1 months). Before coming to transplantation, 28% had received oral melphalan (MEL), 98% received other chemotherapy and 34% received radiation. A single APBSCT was provided for 68, and 32% underwent APBSCT more than once. High-dose MEL alone was used as the preparative regimen for 83%, and the remainder received at least one APBSCT with a more intensive preparative regimen. Ten patients (12%) developed MDS. The 5-year cumulative incidence is 18% (95% confidence interval, 9–30%). There were no demographic factors associated with an increased risk of developing MDS. Median survival after the diagnosis of MDS was 18 months. There is a relatively high risk of MDS after APBSCT for myeloma, and optimal therapy has not been established for these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  3. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  5. Levy V, Katsahian S, Fermand JP, Mary JY, Chevret S . A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine 2005; 84: 250–260.

    Article  CAS  PubMed  Google Scholar 

  6. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294.

    Article  CAS  PubMed  Google Scholar 

  8. Jantunen E, Itala M, Siitonen T, Koivunen E, Leppa S, Juvonen E et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990–2003. Eur J Haematol 2006; 77: 114–119.

    Article  CAS  PubMed  Google Scholar 

  9. Pedersen-Bjergaard J, Andersen MK, Christiansen DH . Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273–3279.

    CAS  PubMed  Google Scholar 

  10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  PubMed  Google Scholar 

  11. Qumsiyeh MB, Tharapel SA . Interphase detection of trisomy 12 in B-cell chronic lymphocytic leukemia by fluorescence hybridization in situ. Leukemia 1992; 6: 602–605.

    CAS  PubMed  Google Scholar 

  12. Coviello V, Boggess M . Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103–112.

    Article  Google Scholar 

  13. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349–353.

    Article  CAS  PubMed  Google Scholar 

  14. Sobecks RM, Le Beau MM, Anastasi J, Williams SF . Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1161–1165.

    Article  CAS  PubMed  Google Scholar 

  15. Del Canizo M, Amigo M, Hernandez JM, Sanz G, Nunez R, Carreras E et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. Haematologica 2000; 85: 403–409.

    CAS  PubMed  Google Scholar 

  16. Sevilla J, Rodriguez A, Hernandez-Maraver D, de Bustos G, Aguado J, Ojeda E et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002; 81: 11–15.

    Article  CAS  PubMed  Google Scholar 

  17. Laurenti L, Chiusolo P, Garzia MG, Zini G, Sora F, Piccirillo N et al. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Haematologica 2002; 87: 59–66.

    PubMed  Google Scholar 

  18. Amigo ML, Del Canizo MC, Hernandez JM, Gonzalez MB, Gutiérrez N, Mateos MV et al. Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia 1998; 12: 1497–1499.

    Article  CAS  PubMed  Google Scholar 

  19. Abruzzese E, Radford JE, Miller JS, Vredenburgh JJ, Rao PN, Pettenati MJ et al. Detection of abnormal clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814–1819.

    CAS  PubMed  Google Scholar 

  20. Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37: 183–189.

    Article  CAS  PubMed  Google Scholar 

  21. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578–2585.

    CAS  PubMed  Google Scholar 

  22. Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20: 737–743.

    Article  CAS  PubMed  Google Scholar 

  23. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  PubMed  Google Scholar 

  24. Yakoub-Agha I, De La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients—report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000; 18: 963–971.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr Sugandhi A Tharapel for providing assistance with the cytogenetic analyses.

Author information

Authors and Affiliations

  1. University of Tennessee Blood and Marrow Transplant Center, Memphis, TN, USA

    D Przepiorka, F Buadi, B McClune, G Franz, W Walsh & F White

Authors
  1. D Przepiorka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Buadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B McClune
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Franz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Przepiorka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Przepiorka, D., Buadi, F., McClune, B. et al. Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant 40, 759–764 (2007). https://doi.org/10.1038/sj.bmt.1705814

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705814

Keywords

This article is cited by

Search

Advanced search

Quick links